Does Wegovy contain a GLP-1? What semaglutide actually is

The common misconception: Wegovy doesn't literally contain GLP-1

A lot of people searching this question have heard that Wegovy is a "GLP-1 medicine" and assume the injection is delivering the hormone GLP-1 directly into their body. That's understandable, and technically not quite right. If you're curious about what Wegovy contains, the short answer is semaglutide, a synthetic molecule that binds to and activates GLP-1 receptors. Think of it as a key engineered to fit a particular lock: the lock is the GLP-1 receptor, and semaglutide is a purpose-built key rather than the body's own one.

Natural GLP-1 is released from cells in the gut after eating and has a half-life measured in minutes, it's degraded almost as quickly as it's produced. Semaglutide, by contrast, is modified at a molecular level so that the enzyme that normally destroys GLP-1 can't break it down as easily. The result is a molecule that stays active for around seven days, which is what makes a once-weekly injection feasible. You can read more about semaglutide's pharmacology on the NHS semaglutide medicines page.

This isn't a semantic quibble. It matters because it explains why semaglutide behaves differently to the natural hormone, more consistent appetite suppression across the week rather than brief post-meal signals, and a more pronounced effect on the brain's satiety centres. It also explains the side-effect profile: because the GLP-1 pathway also governs gastric emptying, activating it persistently can produce nausea, particularly at the start of treatment or after a dose increase.

What GLP-1 receptor activation does, and what Wegovy's single pathway means

GLP-1 receptors are found in the pancreas, the gut wall, the heart, and the hypothalamus region of the brain. When semaglutide binds to them it does several things at once: it slows how quickly food moves out of the stomach (gastric emptying), reduces appetite signals in the brain, and (relevant mainly in people with type 2 diabetes) stimulates insulin release in response to glucose. For weight management, the appetite and gastric-emptying effects are what matter most.

Wegovy is what clinicians call a single-agonist: it acts on one receptor type, GLP-1. This distinguishes it from tirzepatide (Mounjaro), which activates both GLP-1 and GIP receptors simultaneously. Our semaglutide overview covers this distinction if you're comparing the two. The NICE appraisal of semaglutide for weight management (TA875) noted that the GLP-1 mechanism is well-evidenced for weight reduction in adults with obesity, recommending it under specific clinical criteria including BMI thresholds and comorbidities.

Common side effects arising from GLP-1 activation include nausea, vomiting, diarrhoea, constipation, and indigestion, typically most noticeable in the first few weeks or after a dose step up. Serious but infrequent effects include acute pancreatitis; the MHRA issued a Drug Safety Update in January 2026 reminding prescribers and patients to watch for severe, persistent stomach pain that radiates to the back, and to seek urgent medical care if it occurs. Any suspected side effects can be reported at the MHRA's Yellow Card scheme.

Wegovy's licensed place in UK weight management

In the UK, Wegovy is licensed for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. A prescriber reviews your full medical picture (not just your BMI) before deciding whether it's appropriate.

It is worth being clear about one common mix-up. Ozempic is also semaglutide, and it acts on exactly the same GLP-1 receptors. But it carries a UK licence for type 2 diabetes management, not for weight loss. Prescribing Ozempic for weight loss would be off-licence. The page on whether Ozempic contains semaglutide explains this distinction in full. For weight management, the licensed product is Wegovy. If you want to explore what other medicines contain semaglutide, the guide to semaglutide-containing medicines sets them out clearly.

The STEP 1 trial (a 68-week study published in the New England Journal of Medicine) found that adults using semaglutide 2.4mg alongside lifestyle changes lost around 15% of body weight on average. The newer 7.2mg dose approved by the MHRA in April 2026 showed approximately 20.7% average weight loss over 72 weeks in trials, narrowing the gap with tirzepatide. For a broader look at how Wegovy works and what the NHS access picture looks like, the Wegovy overview page covers both.

Storage is straightforward once you're settled into a routine: keep your Wegovy pen in the fridge at 2–8°C, many people tuck it in the fridge door so it's easy to find on injection day. The exact rules for any brief period outside the fridge are set out in the Patient Information Leaflet for your specific pen, and your prescriber is the right person to ask if you're unsure.

If you're thinking about the cost side of private Wegovy treatment, the Wegovy cost guide explains how UK private pricing works and what a transparent all-in price should include. When you're ready to talk through whether Wegovy is suitable for you, start your free consultation with our prescribers.